WAVE Life Sciences (WVE)
(Real Time Quote from BATS)
$5.85 USD
-0.13 (-2.17%)
Updated Aug 8, 2024 01:51 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
Brokerage Reports
WAVE Life Sciences Ltd. [WVE]
Reports for Purchase
Showing records 41 - 60 ( 60 total )
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Not Throwing in the Towel Just Yet; Target Lowered to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Thoughts Into the Watershed PRECISION HD2 Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Reiterates DMD and HD Data During 4Q19: Set Up to Be the Biggest Mover in Our Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Muscular Dystrophy BD Teams Might Want to Take Notice of the New Kid on the Block
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Certitude on Data Timing Should Alleviate Pressure on the Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
DYSTANCE 51 Underway; Speed of Enrollment Predicated Upon OLE Study Biopsy Data Prior to YE19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
A Show Me Story With Company/Platform Defining Events During 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Systemic Therapy of DMD With Stereopure PS-ASO''s Remains Uncertain; Removing From Our Model and Lowering Target to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
2019 Is the Year When the Rubber Meets the Road: Model Updates Post Recent Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Limited Clarity From the Positive Safety Findings; Awaiting Formal Presentation at a Scientific Venue
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
3Q18 Corporate Update; Clinically, Not Much New to Write Home About
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
A Few More Months to the First-in-Human Data With Stereopure ASO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Stereopure Oligos: A Road Less Traveled; Assuming Coverage With a Buy and $49 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-120101 and WVE-120102 Enter the Clinic for Huntington''s Disease; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
IND Filings for WVE-120101 and WVE-120102 to Treat Huntington''s Disease (HD)Expected Mid-2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy rating and a $41 12-month price target
Provider: H.C. Wainwright & Co., Inc.